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Aim of the study: Genistein, an iso-
flavonoid, plays roles in the inhibition 
of protein tyrosine kinase phosphory-
lation, induction of apoptosis, and cell 
differentiation in breast cancer. This 
study aims to induce cellular stress by 
exposing genistein to determine alter-
ations of miRNA expression profiles in 
MCF-7 cells.
Material and methods: XTT assay and 
trypan blue dye exclusion assays were 
performed to examine the cytotoxic 
effects of genistein treatment. Expres-
sions of miRNAs were quantified us-
ing Real-Time Online RT-PCR. 
Results: The IC
50
 dose of genistein 
was 175 μM in MCF-7 cell, line and 
the cytotoxic effect of genistein was 
detected after 48 hours. miR-23b was 
found to be up-regulated 56.69 fold 
following the treatment of genistein. 
It was found that miR-23b was up- 
regulated for MCF-7 breast cancer 
cells after genistein treatment. 
Conclusions: Up-regulated ex-expres- 
sion of miR-23b might be a  puta-
tive biomarker for use in the therapy 
of breast cancer patients. miR-23b 
up-regulation might be important in 
terms of response to genistein. 
Key words: breast cancer, genistein, 
miRNA, MCF-7. 
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Introduction
Breast cancer is the most common cancer type among women. After respi-
ratory cancers, including lung and respiratory tract cancers, breast cancer is 
the second leading cause of death among women [1]. Incidence and mortality 
rates of breast cancer may differ depending on the age, ethnicity, and socio-
economic status of patients [2]. The presence or absence of oestrogen recep-
tor (ER), progesterone receptor (PR), and HER2/Neu receptor determine the 
sub-molecular classification and progression of breast cancer [3]. miRNAs are 
non-coding small RNA molecules (17–24 nucleotide) that repress mRNA tran-
scription when they bind to their target region (3’ untranslated region). Re- 
regulation of expression profiles of miRNAs has a putative role in cancer 
development [4]. Decreasing expression of miRNA that suppress mRNA of 
oncogene, or increasing of expression of miRNA that suppress mRNA of tu-
mour suppressor gene, can trigger the cancer process [4, 5]. It has been demon-
strated that oncomirs such as miR-21, miR-27a, miR-155, and miR-145 exhibit 
different expression patterns between breast cancer cells and non-cancerous 
breast cells [6–8]. In addition to this difference, altered miRNA expression pro-
file is detected differently among molecular sub-types of breast cancer [9]. 
Abnormal miRNA expression pattern can induce angiogenesis and metastasis 
in breast cancer tumours [10]. miRNA dysregulation in breast cancer is also 
associated with poor survival and poor therapeutic outcome [11, 12]. 
Genistein, an isoflavonoid, is a prime anti-cancer component of soybean, 
and it plays roles in the inhibition of protein tyrosine kinase phosphorylation, 
induction of apoptosis, and cell differentiation in breast cancer [13]. The inter-
action between genistein and oestrogen receptor signalling pathway in breast 
cancer has been well characterised. Genistein induces oestrogen-dependent 
cell growth and up-regulation of ER expression, thus it has a potential impact 
for hormone therapy [14, 15]. Genistein-mediated ERα expression is associat-
ed with histone modification changes and genistein re-sensitises ERα-nega-
tive breast cancer cells to tamoxifen [16]. Although it has been known that 
genistein affects chemotherapy agent efficiency and apoptosis, the effect of 
genistein on miRNA profiles is still unknown for breast cancer. This study aims 
to induce cellular stress by exposing genistein to determine the IC
50
 doses of 
treatment conditions in MCF-7 cells. This study also aims to evaluate the sin-
gle effect in terms of miRNA expression levels.
Material and methods
Tumour cell line
Breast cancer cell line (MCF-7), which was purchased from ATCC, was 
used as a breast cancer model.
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Cell culture 
Breast cancer cell line (MCF-7) was cultured in RPMI-
1640 medium supplemented with 100 IU/ml penicillin, 
10 mg/ml streptomycin, 1% L-glutamine, and 10% heat-in-
activated foetal bovine serum, at 37°C in a humidified 
95% air 5% CO
2 
atmosphere. 
Treatment of genistein and cytotoxicity assay
MCF-7 cells were incubated at a density of 2 × 105 cells/
ml of medium using 96-well plates for 24, 48, and 72 
hours. Studied concentrations of genistein were 75 µM, 
100 µM, 125 µM, 150 µM, 175 µM, and 200 µM. XTT assay 
and trypan blue dye exclusion assays were performed to 
examine the cytotoxic effect of IC
50
 dose of genistein in 
the MCF-7 cell line. Formazan formation was quantified 
spectrophotometrically at 450 nM (reference wavelength 
620 nM) with a microplate reader. Viability was calculated 
using the background-corrected absorbance. Cells without 
any treatment were taken as a control group.
Isolation of miRNA
miRNA was isolated from cells exposed to IC
50
 dose of 
genistein and the control group. Isolation of miRNA and 
cDNA synthesis was performed using RT2 qPCR-Grade 
miRNA Isolation Kit and RT2 first Strand Kit, respectively, 
according to the manufacturers’ instructions.
Relative quantification of miRNAs
Relative quantitation of 88 microRNAs (Table 1) was 
measured by using real-time online RT-PCR (LightCycler 
480). SNORD48, SNORD47, SNORD44, U6 were used as 
human endogenous controls. Alterations in the miRNAs 
expressions of genistein were compared to the control 
group. Data analysis was evaluated by ΔΔCT method, 
“Light Cycler® 480 Quantification Software” program, and 
statistical analysis was evaluated with web-based RT2 Pro-
filer PCR Array Data Analysis.
Results
Cytotoxic effect of genistein on MCF-7 cells
Cells were incubated at a density of 2 × 105 cells/ml 
of medium using 96-well plates for 24, 48, and 72 hours. 
Studied concentrations of genistein were 75 µM, 100 µM, 
125 µM, 150 µM, 175 µM, and 200 µM (Fig. 1). Untreated 
MCF-7 cells were considered as a control group. The IC
50
 
dose of genistein was 175 µM and the cytotoxic effect of 
genistein was detected after 48 hours. 
miR-23b is up-regulated miRNA by genistein 
in MCF-7 cell line 
Alterations in the expressions of miRNAs were com-
pared with genistein untreated MCF-7 cells. miRNA ex-
pression was detected 48 hours after genistein treatment. 
SNORD44, SNORD47, SNORD48, and U6 genes were 
Table 1. Target and housekeeping miRNAs that were analysed for the genistein group. Expression analyses for 88 target miRNAs were per-
formed by real-time PCR. Table 1 describes the sequences of miRNAs 
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used for housekeeping miRNAs as the endogenous nor-
malisation factor to define miRNA expression profiles of 
88 miRNAs. miR-23b was found to be up-regulated 56.69 
fold in the treatment of genistein compared to the control 
group of genistein untreated cells (Fig. 2). 
Discussion
Several studies have reported that genistein, which 
is an isoflavonoid and is a prime anti-cancer component 
of soybean, can affect miRNA expression levels [17–20]. 
miR-151, which has an oncogenic effect, is up-regulated in 
prostate cancer cell lines (PCa), and genistein treatment 
down-regulates the relative expression of miR-151 in PCa 
[21]. It is known that genistein induces expression of miR-
574-3p, which has a tumour suppressor role, and this in-
duction inhibits cell proliferation, migration, and invasion 
in vitro and in vivo for prostate cancers [22]. Zaman et al. 
showed that genistein decreases the expression of miR-
23b-3p in A-498 renal cancer cell line [23]. Furthermore, 
suppression of miR-23b-3p increases the number of total 
apoptotic cells and decreases cell invasion [23]. Although it 
is known that genistein affects chemotherapy agent effi-
ciency and apoptosis, the effect of genistein on miRNA pro-
files is still unknown for breast cancer. In this study, it was 
found that treatment condition, which was genistein, af-
fected miRNA expressions in MCF-7 breast cancer cell line. 
The cytotoxic effects of the defined group were examined 
independently. Cells in the genistein group were treated 
with an IC
50
 dose of genistein for three days. The cytotox-
ic effect of treatment group was observed after 48 hours. 
After the IC
50 
dose of genistein was determined, miRNA 
qPCR array method was performed to detect regulation 
of miRNAs expressions in MCF-7 cell line. In this study, it 
was found that expression of miR-23b was up-regulated in 
the genistein treatment group. Majid et al. clearly showed 
that miR-23b is a methylation-silenced tumour suppressor 
in prostate cancer, and a high expression level of miR-23b 
is associated with higher survival rates in prostate can-
cer patients [24]. Stabile ectopic expression of miR-23b in 
HCT-116 colon carcinoma cell line reduces migration, inva-
sion, and resistance to anoikis [25]. In vivo tumour models, 
which are generated from miR-23b-expressing HCT 116 
cells, show that miR-23b-expressing tumours are encap-
sulated, non-invasive, and have low growth rate [25]. miR-
23b regulates colony morphology and increases epithelial 
characteristics in MCF-7 cells. It is observed that miR-23b 
enhances focal adhesion connections and provides less 
lamellipodia structure after transfection in MDA-MB-231 
breast cancer cells [26]. miR-23b regulates cytoskeletal 
reorganization and reduces cell motility and invasion via 
the PAK2 gene, which is a target for miR-23b in MCF-7 and 
MDA-MB-231 cells [26]. Furthermore, inhibition of miR-23b 
increases cell migration and metastasis for in vivo breast 
cancer models [26]. Because it is known that miR-23b has 
Fig. 2. miRNA expression profiles after treatment. For the genistein group, miR-23b was up-regulated 56.69 fold after treatment. miRNA 
expression visualization about log2 (Fold Change) associated with genistein, compared with control
Fig. 1. Dose-dependent cytotoxicity of genistein. MCF-7 cells were 
treated with various concentrations of genistein. The studied concen-
trations of genistein were 75 µM, 100 µM, 125 µM, 150 µM, 175 µM, 
and 200 µM. The IC50 dose of genistein was 175 µM
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a tumour suppressor role for metastasis of breast cancer 
cells, miR-23b up-regulation might be important in terms 
of response to genistein. 
In conclusion, up-regulated expression of miR-23b 
might be a putative biomarker for use in the therapy of 
breast cancer patients. 
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